These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 18471305)

  • 1. Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer.
    Tsuruma T; Iwayama Y; Ohmura T; Katsuramaki T; Hata F; Furuhata T; Yamaguchi K; Kimura Y; Torigoe T; Toyota N; Yagihashi A; Hirohashi Y; Asanuma H; Shimozawa K; Okazaki M; Mizushima Y; Nomura N; Sato N; Hirata K
    J Transl Med; 2008 May; 6():24. PubMed ID: 18471305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenic enhancement and clinical effect by type-I interferon of anti-apoptotic protein, survivin-derived peptide vaccine, in advanced colorectal cancer patients.
    Kameshima H; Tsuruma T; Torigoe T; Takahashi A; Hirohashi Y; Tamura Y; Tsukahara T; Ichimiya S; Kanaseki T; Iwayama Y; Sato N; Hirata K
    Cancer Sci; 2011 Jun; 102(6):1181-7. PubMed ID: 21371173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical trial of survivin-derived peptide vaccine therapy for patients with advanced or recurrent oral cancer.
    Miyazaki A; Kobayashi J; Torigoe T; Hirohashi Y; Yamamoto T; Yamaguchi A; Asanuma H; Takahashi A; Michifuri Y; Nakamori K; Nagai I; Sato N; Hiratsuka H
    Cancer Sci; 2011 Feb; 102(2):324-9. PubMed ID: 21143701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors.
    Lennerz V; Gross S; Gallerani E; Sessa C; Mach N; Boehm S; Hess D; von Boehmer L; Knuth A; Ochsenbein AF; Gnad-Vogt U; Zieschang J; Forssmann U; Woelfel T; Kaempgen E
    Cancer Immunol Immunother; 2014 Apr; 63(4):381-94. PubMed ID: 24487961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Anti-apoptosis protein, survivin-2B-derived peptide vaccine therapy].
    Tsuruma T; Torigoe T; Hata F; Furuhata T; Sato N; Hirata K
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1634-6. PubMed ID: 15553667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I clinical study of anti-apoptosis protein survivin-derived peptide vaccination for patients with advanced or recurrent urothelial cancer.
    Honma I; Kitamura H; Torigoe T; Takahashi A; Tanaka T; Sato E; Hirohashi Y; Masumori N; Tsukamoto T; Sato N
    Cancer Immunol Immunother; 2009 Nov; 58(11):1801-7. PubMed ID: 19294381
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential survival benefit of anti-apoptosis protein: survivin-derived peptide vaccine with and without interferon alpha therapy for patients with advanced or recurrent urothelial cancer--results from phase I clinical trials.
    Tanaka T; Kitamura H; Inoue R; Nishida S; Takahashi-Takaya A; Kawami S; Torigoe T; Hirohashi Y; Tsukamoto T; Sato N; Masumori N
    Clin Dev Immunol; 2013; 2013():262967. PubMed ID: 24363758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin.
    Wobser M; Keikavoussi P; Kunzmann V; Weininger M; Andersen MH; Becker JC
    Cancer Immunol Immunother; 2006 Oct; 55(10):1294-8. PubMed ID: 16315030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients.
    Kameshima H; Tsuruma T; Kutomi G; Shima H; Iwayama Y; Kimura Y; Imamura M; Torigoe T; Takahashi A; Hirohashi Y; Tamura Y; Tsukahara T; Kanaseki T; Sato N; Hirata K
    Cancer Sci; 2013 Jan; 104(1):124-9. PubMed ID: 23078230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins.
    Idenoue S; Hirohashi Y; Torigoe T; Sato Y; Tamura Y; Hariu H; Yamamoto M; Kurotaki T; Tsuruma T; Asanuma H; Kanaseki T; Ikeda H; Kashiwagi K; Okazaki M; Sasaki K; Sato T; Ohmura T; Hata F; Yamaguchi K; Hirata K; Sato N
    Clin Cancer Res; 2005 Feb; 11(4):1474-82. PubMed ID: 15746049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer.
    Tsuruma T; Hata F; Torigoe T; Furuhata T; Idenoue S; Kurotaki T; Yamamoto M; Yagihashi A; Ohmura T; Yamaguchi K; Katsuramaki T; Yasoshima T; Sasaki K; Mizushima Y; Minamida H; Kimura H; Akiyama M; Hirohashi Y; Asanuma H; Tamura Y; Shimozawa K; Sato N; Hirata K
    J Transl Med; 2004 Jun; 2(1):19. PubMed ID: 15193151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic effect of a T helper cell supported CTL response induced by a survivin peptide vaccine against murine cerebral glioma.
    Ciesielski MJ; Kozbor D; Castanaro CA; Barone TA; Fenstermaker RA
    Cancer Immunol Immunother; 2008 Dec; 57(12):1827-35. PubMed ID: 18438666
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Antitumor immunotherapy with the use of synthetic fragments of survivin].
    Volkova TD; Koroev DO; Titova MA; Oboznaia MB; Filatova MP; Pankratov AA; Morozova NB; Zolotavkina IuB; Iakubovskaia RI; Vol'pina OM
    Bioorg Khim; 2008; 34(4):457-63. PubMed ID: 18695717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor specific expression of survivin-2B in lung cancer as a novel target of immunotherapy.
    Ichiki Y; Hanagiri T; Takenoyama M; Baba T; Fukuyama T; Nagata Y; Mizukami M; So T; Sugaya M; Yasuda M; So T; Sugio K; Yasumoto K
    Lung Cancer; 2005 May; 48(2):281-9. PubMed ID: 15829330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baseline levels of CD8+ T cells against survivin and survivin-2B in the blood of lung cancer patients and cancer-free individuals.
    Karanikas V; Soukou F; Kalala F; Kerenidi T; Grammoustianou ES; Gourgoulianis KI; Germenis AE
    Clin Immunol; 2008 Nov; 129(2):230-40. PubMed ID: 18789878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA-A24-positive pancreatic adenocarcinoma.
    Shima H; Tsurita G; Wada S; Hirohashi Y; Yasui H; Hayashi H; Miyakoshi T; Watanabe K; Murai A; Asanuma H; Tokita S; Kubo T; Nakatsugawa M; Kanaseki T; Tsukahara T; Nakae Y; Sugita O; Ito YM; Ota Y; Kimura Y; Kutomi G; Hirata K; Mizuguchi T; Imai K; Takemasa I; Sato N; Torigoe T
    Cancer Sci; 2019 Aug; 110(8):2378-2385. PubMed ID: 31218770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients.
    Widenmeyer M; Griesemann H; Stevanović S; Feyerabend S; Klein R; Attig S; Hennenlotter J; Wernet D; Kuprash DV; Sazykin AY; Pascolo S; Stenzl A; Gouttefangeas C; Rammensee HG
    Int J Cancer; 2012 Jul; 131(1):140-9. PubMed ID: 21858810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma.
    Weber J; Sondak VK; Scotland R; Phillip R; Wang F; Rubio V; Stuge TB; Groshen SG; Gee C; Jeffery GG; Sian S; Lee PP
    Cancer; 2003 Jan; 97(1):186-200. PubMed ID: 12491520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunohistological analysis of pancreatic carcinoma after vaccination with survivin 2B peptide: Analysis of an autopsy series.
    Kubo T; Tsurita G; Hirohashi Y; Yasui H; Ota Y; Watanabe K; Murai A; Matsuo K; Asanuma H; Shima H; Wada S; Nakatsugawa M; Kanaseki T; Tsukahara T; Mizuguchi T; Hirata K; Takemasa I; Imai K; Sato N; Torigoe T
    Cancer Sci; 2019 Aug; 110(8):2386-2395. PubMed ID: 31206934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case report: Long-term survival of a pancreatic cancer patient immunized with an SVN-2B peptide vaccine.
    Shima H; Kutomi G; Satomi F; Imamura M; Kimura Y; Mizuguchi T; Watanabe K; Takahashi A; Murai A; Tsukahara T; Kanaseki T; Hirohashi Y; Iwayama Y; Tsuruma T; Kameshima H; Sato N; Torigoe T; Takemasa I
    Cancer Immunol Immunother; 2018 Oct; 67(10):1603-1609. PubMed ID: 30069687
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.